Arterial remodeling in B-type natriuretic peptide knock-out females

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Holditch, Sara J ^a   Schreiber, Claire A ^a   Burnett, John C ^a   Ikeda, Yasuhiro ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ANIMAL; BLOOD PRESSURE; DAHL RAT; DEFICIENCY; FEMALE; GENETICS; HUMAN; HYPERTENSION; MALE; MESENTERIC ARTERY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; POLYARTERITIS NODOSA; SEX FACTOR; TIME FACTOR; VASCULAR REMODELING; VASCULITIS;

ANIMALS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MESENTERIC ARTERIES; NATRIURETIC PEPTIDE, BRAIN; POLYARTERITIS NODOSA; RATS, INBRED DAHL; SEX FACTORS; TIME FACTORS; VASCULAR REMODELING; VASCULITIS;

EID: 84969255822     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25623     Document Type: Article

References (58)

1. Greiten, L. E., Holditch, S. J., Arunachalam, S. P. and Miller, V. M. Should there be sex-specific criteria for the diagnosis and treatment of heart failure? J Cardiovasc Transl Res 7, 139-155, doi: 10.1007/s12265-013-9514-8 (2014).
2. Barton, M. and Meyer, M. R. Postmenopausal hypertension: mechanisms and therapy. Hypertension 54, 11-18, doi: 10.1161/ HYPERTENSIONAHA.108.120022 (2009).
3. Villard, C., Swedenborg, J., Eriksson, P. and Hultgren, R. Reproductive history in women with abdominal aortic aneurysms. J Vasc Surg 54, 341-345, 345 e341-342, doi: 10.1016/j.jvs.2010.12.069 (2011).
4. Rosendaal, F. R., Helmerhorst, F. M. and Vandenbroucke, J. P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22, 201-210 (2002).
5. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Womens Health Initiative randomized controlled trial. Jama 288, 321-333 (2002).
6. Pauriah, M. et al. B-type natriuretic peptide is an independent predictor of endothelial function in man. Clin Sci (Lond) 123, 307-312, doi: 10.1042/CS20110168 (2012).
7. Rubattu, S., Sciarretta, S., Valenti, V., Stanzione, R. and Volpe, M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21, 733-741, doi: 10.1038/ajh.2008.174 (2008).
8. Pandey, K. N. The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms. Febs J 278, 1792-1807, doi: 10.1111/j.1742-4658.2011.08081.x (2011).
9. Huntley, B. K. et al. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol 209, 943-949, doi: 10.1002/jcp.20793 (2006).
10. Cohen, D., Koh, G. Y., Nikonova, L. N., Porter, J. G. and Maack, T. Molecular determinants of the clearance function of type C receptors of natriuretic peptides. J Biol Chem 271, 9863-9869 (1996).
11. Kuhn, M. et al. The natriuretic peptide/guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 119, 2019-2030, doi: 10.1172/JCI37430 (2009).
12. Kishimoto, I. et al. Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart. Curr Cardiol Rev 5, 45-51, doi: 10.2174/157340309787048068 (2009).
13. Tokudome, T. et al. Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol 29, 1516-1521, doi: 10.1161/ATVBAHA.109.187526 (2009).
14. Tokudome, T. et al. Importance of Endogenous Atrial and Brain Natriuretic Peptides in Murine Embryonic Vascular and Organ Development. Endocrinology, en20151344, doi: 10.1210/en.2015-1344 (2015).
15. Tamura, N. et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97, 4239-4244, doi: 10.1073/ pnas.070371497 (2000).
16. Ogawa, Y., Tamura, N., Chusho, H. and Nakao, K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79, 723-729 (2001).
17. Suganami, T. et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol 12, 2652-2663 (2001).
18. Makino, H. et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 49, 2514-2524, doi: 10.1007/s00125-006-0352-y (2006).
19. Holditch, S. J. et al. B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension. Hypertension 66, 199-210, doi: 10.1161/HYPERTENSIONAHA.115.05610 (2015).
20. Cataliotti, A. et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 123, 1297-1305, doi: 10.1161/CIRCULATIONAHA.110.981720 (2011).
21. Tonne, J. M. et al. Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. Aging (Albany NY) 6, 311-319 (2014).
22. Wang, T. J. et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90, 254-258 (2002).
23. Naruse, M. et al. Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension 23, I231-234 (1994).
24. Sayama, H., Nakamura, Y., Saito, N. and Kinoshita, M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 10, 537-540 (1999).
25. Geurts, A. M. et al. Generation of gene-specific mutated rats using zinc-finger nucleases. Methods Mol Biol 597, 211-225, doi: 10.1007/978-1-60327-389-3-15 (2010).
26. Yanes, L. L. and Reckelhoff, J. F. Postmenopausal hypertension. Am J Hypertens 24, 740-749, doi: 10.1038/ajh.2011.71 (2011).
27. Burt, V. L. et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25, 305-313 (1995).
28. Scotland, R. S. et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111, 796-803, doi: 10.1161/01.CIR.0000155238.70797.4E (2005).
29. Hinojosa-Laborde, C., Lange, D. L. and Haywood, J. R. Role of female sex hormones in the development and reversal of dahl hypertension. Hypertension 35, 484-489 (2000).
30. Moyes, A. J. et al. Endothelial C-type natriuretic peptide maintains vascular homeostasis. J Clin Invest 124, 4039-4051, doi: 10.1172/ JCI74281 (2014).
31. Wilens, S. L. and Sproul, E. E. Spontaneous cardiovascular disease in the rat: II. Lesions of the Vascular System. Am J Pathol 14, 201-216 205 (1938).
32. Cutts, J. H. Vascular lesions resembling polyarteritis nodosa in rats undergoing prolonged stimulation with oestrogen. Br J Exp Pathol 47, 401-404 (1966).
33. Race, G. J. and Peschel, E. Pathogenesis of polyarteritis nodosa in hypertensive rats. Circ Res 2, 483-487 (1954).
34. Kempner, W., Preschel, E. and Blackschaffer, B. Effect of diet on experimental hypertension and on the development of polyarteritis nodosa in rats. Circ Res 3, 73-78 (1955).
35. Rapp, J. P. and Dene, H. Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. Hypertension 7, 340-349 (1985).
36. Suzuki, T., Oboshi, S. and Sato, R. Periarteritis nodosa in spontaneously hypertensive rats-incidence and distribution. Acta Pathol Jpn 29, 697-703 (1979).
37. Radomski, M. W., Palmer, R. M. and Moncada, S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2, 1057-1058 (1987).
38. Yan, Z. Q., Yokota, T., Zhang, W. and Hansson, G. K. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 79, 38-44 (1996).
39. Tanner, F. C. et al. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 101, 1982-1989 (2000).
40. Sarkar, R., Meinberg, E. G., Stanley, J. C., Gordon, D. and Webb, R. C. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 78, 225-230 (1996).
41. Garg, U. C. and Hassid, A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 171, 474-479 (1990).
42. Dupuis, M. et al. Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation 110, 867-873, doi: 10.1161/01.CIR.0000138850.72900.FE (2004).
43. Schmidt, A., Geigenmueller, S., Voelker, W., Seiler, P. and Buddecke, E. Exogenous nitric oxide causes overexpression of TGF-beta1 and overproduction of extracellular matrix in human coronary smooth muscle cells. Cardiovasc Res 58, 671-678 (2003).
44. Gurjar, M. V., Sharma, R. V. and Bhalla, R. C. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 19, 2871-2877 (1999).
45. Ueno, H. et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 96, 2272-2279 (1997).
46. Shinomiya, M. et al. C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. Biochem Biophys Res Commun 205, 1051-1056, doi: 10.1006/bbrc.1994.2772 (1994).
47. Gaspari, T. A., Barber, M. N., Woods, R. L. and Dusting, G. J. Type-C natriuretic peptide prevents development of experimental atherosclerosis in rabbits. Clin Exp Pharmacol Physiol 27, 653-655 (2000).
48. Clarkson, T. B. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14, 373-384, doi: 10.1097/GME.0b013e31803c764d (2007).
49. Barrett-Connor, E. and Bush, T. L. Estrogen and coronary heart disease in women. Jama 265, 1861-1867 (1991).
50. Westendorp, I. C. et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. Stroke 30, 2562-2567 (1999).
51. Sumino, H. et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 28, 579-584, doi: 10.1291/hypres.28.579 (2005).
52. Canonico, M. et al. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Womens Health Initiative Hormone Therapy clinical trials. Menopause 21, 214-220, doi: 10.1097/GME.0b013e31829752e0 (2014).
53. Guillevin, L., Le Thi Huong, D., Godeau, P., Jais, P. and Wechsler, B. Clinical findings and prognosis of polyarteritis nodosa and Churg- Strauss angiitis: a study in 165 patients. Br J Rheumatol 27, 258-264 (1988).
54. Falcini, F. et al. Clinical overview and outcome in a cohort of children with polyarteritis nodosa. Clin Exp Rheumatol 32, S134-137 (2014).
55. Yougbare, I. et al. Cyclic GMP catabolism up-regulation in MRL/lpr lupus-prone mice is associated with organ remodeling. Biochim Biophys Acta 1842, 916-926, doi: 10.1016/j.bbadis.2014.03.001 (2014).
56. Slavin, R. E. and Gonzalez-Vitale, J. C. Segmental mediolytic arteritis: a clinical pathologic study. Lab Invest 35, 23-29 (1976).
57. Shenouda, M., Riga, C., Naji, Y. and Renton, S. Segmental arterial mediolysis: a systematic review of 85 cases. Ann Vasc Surg 28, 269-277, doi: 10.1016/j.avsg.2013.03.003 (2014).
58. Cataliotti, A., Chen, H. H., Redfield, M. M. and Burnett, J. C., Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Heart Fail Clin 2, 269-276, doi: 10.1016/j.hfc.2006.09.002 (2006).